Key PointsEven if you put money to work just before the last bear market started, in theory making a terrible timing call, you’d have captured a 73% total return.
(RTTNews) - Germany's equity benchmark DAX fell to a near 9-week low on Thursday as stocks tumbled on inflation and interest rate concerns amid elevated oil prices and bond yields due to persisting geopolitical tensions.
(RTTNews) - CollPlant Biotechnologies Ltd(CLGN), a regenerative medicine and technology company, announced its second-quarter 2026 financial results, reflecting a narrower net loss.
(RTTNews) - Thursday, Zealand Pharma A/S (ZEAL.CO) announced new Phase 3 data for Survodutide, an investigational once-weekly glucagon/GLP-1 receptor dual agonist in patients with obesity, and type 2 diabetes (T2D).
(RTTNews) - The following biotech stocks reached a 52-week high on September 30, 2026, driven by key catalysts such as promising results from clinical trials.
(RTTNews) - PZ Cussons plc (PZC.L), a consumer goods company, on Thursday reported 4.5 percent like-for-like revenue growth in the first quarter of fiscal 2027.
(RTTNews) - Pliant Therapeutics (PLRX), a clinical-stage biotechnology company focused on developing integrin-based therapeutics, announced the appointment of David Raben, M.D., as Chief Medical Officer.
(RTTNews) - CVS Health (CVS), a health solutions company, announced that its board of directors approved a quarterly dividend of $0.665 per share of the corporation's common stock.
The dividend is payable on November 2, 2026, to holders of record on October 22, 2026.
(RTTNews) - Pfizer Inc. (PFE) presented detailed Phase 2 results showing that tilrekimig achieved significant improvements in skin clearance in adults with moderate-to-severe atopic dermatitis, supporting continued development of the investigational therapy.